Mineralys Therapeutics — Third Quarter 2026 Earnings Summary

Mineralys Therapeutics reported a net loss of $57.3 million for the third quarter ended September 30, 2026, driven by increased general and administrative expenses related to commercial launch preparations. The company's cash, cash equivalents, and investments totaled $624.7 million as of September 30, 2026, which is expected to fund operations into 2028. New analyses from the pivotal Launch-HTN trial indicated that 46% of participants with uncontrolled or resistant hypertension achieved a systolic blood pressure target of less than 130 mmHg at Week 12 while receiving lorundrostat 50 mg. The U.S. Food and Drug Administration continues its review of the New Drug Application for lorundrostat, with a Prescription Drug User Fee Act target date set for December 22, 2026.